Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14775366 | 0.77 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3POLBMAPT | |
| SCHEMBL15797503 | 0.76 | DPP4 (0.53) | SLC6A2SLC6A4SLC6A3POLBMAPT | |
| SCHEMBL14775411 | 0.74 | MAPT (0.41) | SLC6A2SLC6A4SLC6A3POLBMAPT | |
| SCHEMBL11989196 | 0.74 | MAPT (0.47) | POLBMAPTTP53P2RX7HRH3 | |
| SCHEMBL14775341 | 0.73 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3MAPTTP53 | |
| SCHEMBL2836180 | 0.71 | CCR3 (0.50) | SLC6A3MC4RHRH3CCR3 | |
| SCHEMBL28870160 | 0.70 | CCR3 (0.63) | SLC6A4SLC6A3MC4RCCR3 | |
| SCHEMBL20231203 | 0.69 | MAPT (0.63) | MAPT | |
| SCHEMBL27887861 | 0.69 | POLB (0.45) | POLB | |
| SCHEMBL13561473 | 0.68 | P2RX7 (0.50) | SLC6A2SLC6A4SLC6A3POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570409-B1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT | SHANGHAI INST PHARM INDUSTRY (CN) | 2015-07-08 | — | — | EP | disclosed |
| US-8962621-B2 | Aralkyl diamine derivatives and uses thereof as antidepressants | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-20130072488-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2013-03-21 | — | — | US | disclosed |
| EP-2570409-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT | Shanghai Institute of Pharmaceutical Industry (CN) | 2013-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072488-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS | MAOA, SLC6A2, MAOB | SLC6A2 2/4885SLC6A4 5/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.